Intelligence Feed event · Policy · 2026-09-03

    Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJM

    Question

    Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJM

    Direct answer

    Revolution Medicines announced the publication of Phase 1/2 clinical data evaluating daraxonrasib in the New England Journal of Medicine. The trial focused on patients with previously treated RAS-mutant non-small cell lung cancer. Results showed a 42% objective response rate alongside median overall survival of 16.0 months, validating the mechanistic efficacy of its selective RAS(ON) inhibitor approach.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-03
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJM”, revision 1, evidence through 2026-09-03. https://marketontology.com/market-events/2026-09-03/revolution-medicines-publishes-phase-1-2-data-for-daraxonrasib-in-nejm-e9900f

    POLICY
    Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJM
    Revolution Medicines announced the publication of Phase 1/2 clinical data evaluating daraxonrasib in the New England Journal of Medicine. The trial focused on patients with previously treated RAS-mutant non-small cell lung cancer. Results showed a 42% objective response rate alongside median overall survival of 16.0 months, validating the mechanistic efficacy of its selective RAS(ON) inhibitor approach.
    RVMD
    Impact
    68
    SEP 3
    SIG
    92%
    RVMD
    Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJM
    Revolution Medicines announced the publication of Phase 1/2 clinical data evaluating daraxonrasib in the New England Journal of Medicine. The trial focused on patients with previously treated RAS-mutant non-small cell lung cancer. Results showed a 42% objective response rate alongside median overall survival of 16.0 months, validating the mechanistic efficacy of its selective RAS(ON) inhibitor approach.
    → A 42% objective response rate and 16.0-month median overall survival in RAS-mutant NSCLC enhances pipeline commercial net present value for RVMD.
    Impact
    Revolution Medicines announced the publication of Phase 1/2 clinical data evaluating daraxonrasib in the New England Journal of Medicine. The trial focused on patients with previously treated RAS-mutant non-small cell lung cancer. Results showed a 42% objective response rate alongside median overall survival of 16.0 months, validating the mechanistic efficacy of its selective RAS(ON) inhibitor approach.
    Affected
    RVMD
    Transmission
    A 42% objective response rate and 16.0-month median overall survival in RAS-mutant NSCLC enhances pipeline commercial net present value for RVMD.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    RVMDclinical pipeline validation and increased regulatory approval probabilityUp1-4wNEJM publication showed 42% ORR and 16.0 months median OS for daraxonrasib in RAS mutant NSCLC.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month